Literature DB >> 3791069

In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease.

O Miatto, R G Gonzalez, F Buonanno, J H Growdon.   

Abstract

In order to study possible metabolic derangements in Alzheimer's disease (AD), we performed phosphorus 31 nuclear magnetic resonance (31P NMR) spectroscopy on brain samples obtained at autopsy from 7 patients with AD and 9 control subjects. Aqueous solutions of brain tissue contained well-defined peaks of intermediate compounds in phospholipid metabolism, including the phosphomonoesters phosphocholine and phosphoethanolamine, and the phosphodiesters glycerophosphorylcholine and glycerophosphorylethanolamine. 31P NMR spectra also displayed the inorganic phosphorus signal, which provides an index to the in vivo concentration of high-energy compounds. We found evidence for altered phospholipid metabolism in that relative levels of phosphomonoesters were decreased, and phosphodiesters increased, in frontal and parietal regions of patients with AD compared to control subjects. The inorganic phosphorus resonance peaks were similar in AD and control subjects, suggesting that energy stores are not diminished in AD. These preliminary data are consistent with the hypothesis that abnormalities in phospholipid metabolism contribute to possible neuronal membrane dysfunction and impaired cholinergic neurotransmission in AD.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791069     DOI: 10.1017/s0317167100037276

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  11 in total

Review 1.  Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids.

Authors:  A A Farooqui; L Liss; L A Horrocks
Journal:  Metab Brain Dis       Date:  1988-03       Impact factor: 3.584

2.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

Review 3.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

Review 4.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids.

Authors:  A Chauhan; I Ray; V P Chauhan
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 6.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

7.  Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls.

Authors:  J N Kanfer; J W Pettegrew; J Moossy; D G McCartney
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

8.  Evidence for a membrane defect in Alzheimer disease brain.

Authors:  R M Nitsch; J K Blusztajn; A G Pittas; B E Slack; J H Growdon; R J Wurtman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 9.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

Review 10.  Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review.

Authors:  Barry S Baumel; P Murali Doraiswamy; Marwan Sabbagh; Richard Wurtman
Journal:  Neurol Ther       Date:  2020-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.